This analysis investigates oncological safety and outcomes in IDC patients undergoing neoadjuvant therapy, suggesting effectiveness with DCIS presence.
Objective This study aim to investigate the oncological safety of neoadjuvant therapy (NAT) followed by breast-conserving surgery (BCS) for invasive ductal carcinoma (IDC) patients with the presence of ductal carcinoma in situ (DCIS) on pre-NAT biopsy.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: